An ongoing theme to expand pharmaceutical manufacturing capacity and the contract manufacturing business, including small-molecule drugs, highly potent drugs, and sterile formulations, by bringing in API manufacturers and contract manufacturers. The CDMO platform from APIs through finished formulations will be strengthened through the construction and commissioning of new manufacturing facilities.